ArticleFrontiers in medicine2025
Integration of gut microbiota, Stroke Dysbiosis Index, and inflammatory biomarkers in assessing prognosis of acute ischemic stroke.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Convergent Gut Microbiome Remodeling Across Ischemic Stroke, Myocardial Infarction, and Longevity Reveals a Shared Ecological Signature of Aging and Disease.International journal of molecular sciences · 2026Article
- Gut dysbiosis, metabolic signals, and pulmonary immune reprogramming: decoding the gut microbiota -immune axis in stroke-associated pneumonia.Frontiers in immunology · 2026Review
- Association and predictive value of systemic immune-inflammation index and body mass index in cervical ossification of the posterior longitudinal ligament.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute ischemic stroke (AIS) is often complicated by systemic infections that worsen prognosis. Emerging evidence suggests gut microbiota dysbiosis, inflammatory biomarkers, and gut-barrier dysfunction play pivotal roles in post-stroke outcomes. This study aimed to integrate Stroke Dysbiosis Index (SDI), Microbial Dysbiosis Index (MDI), and inflammatory biomarkers to evaluate their prognostic value in AIS patients. Methods: An observational prospective cohort was conducted at a tertiary stroke center in Jakarta (September 2023-September 2024). Eighty AIS patients admitted within 24 h of onset were enrolled. Fecal samples underwent 16S rRNA sequencing for microbiota profiling and SDI/MDI calculation. Blood biomarkers (NMDAR NR2B, butyrate, TMAO, RANKL, iFABP, LPS) and platelet-to-lymphocyte ratio (PLR) were measured. Clinical severity was assessed with NIHSS. Outcomes included infection within 7 days, and complications. Statistical analyses comprised correlation, regression, and ROC curve modeling. Results: Infection occurred in 46.3% of patients, predominantly older (>60 years) and female. Infected patients showed reduced microbial diversity, enrichment of pathogenic taxa (Klebsiella, Escherichia, Salmonella), elevated SDI/MDI, and depleted SCFA producers. Biomarkers revealed increased NMDAR, TMAO, iFABP, and LPS, with reduced butyrate and RANKL (all Conclusion: Gut dysbiosis, elevated dysbiosis indices, and inflammatory biomarker derangements were strongly associated with post-stroke infections and adverse prognosis. Integrating microbiota and biomarker profiles with clinical parameters may provide a robust framework for risk stratification and open avenues for microbiota-targeted therapies in AIS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.